Is itrm a stock I should buy to double my earnings? There fda thing is next week


Aime
Iterum Therapeutics (ITRM) is not a strong buy at this time. Here's why:
- Financial Performance: Iterum Therapeutics has reported a net loss of $5 million for the second quarter of 2024, which is a significant reduction from the previous year's net loss of $12.2 million1. However, the company did not report any revenue for the quarter23. This lack of revenue growth is a red flag for investors.
ITRM Net Income YoY, Total Revenue...
- FDA Approval Status: The FDA approval for sulopenem, the company's key drug candidate, is pending with a PDUFA date set for October 25, 20244. While this is a potential milestone, the FDA review process can be unpredictable, and there is no guarantee of approval.
fda review date(1)stock code include itrm(1)fda approval status(1)stock code include itrm ; fda review date ; fda approval status(1)
last-price | last-change% | FDA Review Date | Drug Name | Indication | FDA Review Round | Accelerated Approval Status | Accelerated Approval Pathway | FDA Approval Status | FDA Approval Event Type |
---|---|---|---|---|---|---|---|---|---|
1.17 | 7.34% | 20241025 | Sulopenem | Urinary tract infection | 1 | Accelerated | Accelerated Approval | Pending | PDUFA Date |
1.17 | 7.34% | 20240909 | Sulopenem | Urinary tract infection | 1 | Not Accelerated | -- | Pending | FDA Adcomm |
Ticker |
---|
ITRMIterum Therapeutics |
ITRMIterum Therapeutics |
View 1 result
- Market Sentiment: The stock has experienced a significant decline of 51.8% this year compared to the industry's decrease of 0.8%, which suggests that market sentiment is weak56.
- Analyst Ratings: The consensus EPS for Iterum Therapeutics is -$0.2 for the next quarter, with an average analyst price target of $1.1710. This indicates that analysts do not expect the stock to perform well in the near term.
- Upcoming FDA Decision: While the FDA decision is next week, the uncertainty surrounding the outcome and the potential impact on the stock price makes it a risky proposition to double your earnings.
In conclusion, Iterum Therapeutics is not a stock that presents a strong buying opportunity at this time. The lack of revenue, negative earnings, and uncertain FDA approval status make it a high-risk investment. It is important to exercise caution and consider these factors before making any investment decisions.
Source:
more
less
Continue this conversation 

Explore
Screener
Analysis
Learn
Wiki